Advanced Life Sciences has licensed a patent from the University of Illinois at Chicago for a potential anti-cancer agent called betulinic acid that is derived from birch bark and promotes cancer cell death. Betulinic acid was originally discovered by UIC researchers to have therapeutic properties for treating malignant melanoma, a deadly form of skin cancer. Advanced Life Sciences plans to develop betulinic acid into a drug for clinical use by optimizing its chemical properties using medicinal chemistry techniques.